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Abstract
Background: Clinical pathways (CPs) are used to improve the outcomes of acute stroke, but their use in stroke
care is questionable, because the evidence on their effectiveness is still inconclusive. The objective of this study
was to evaluate whether CPs improve the outcomes and the quality of care provided to patients after acute
ischemic stroke.
Methods: This was a multicentre cluster-randomized trial, in which 14 hospitals were randomized to the CP arm or
to the non intervention/usual care (UC) arm. Healthcare workers in the CP arm received 3 days of training in
quality improvement of CPs and in use of a standardized package including information on evidence-based key
interventions and indicators. Healthcare workers in the usual-care arm followed their standard procedures. The
teams in the CP arm developed their CPs over a 6-month period. The primary end point was mortality. Secondary
end points were: use of diagnostic and therapeutic procedures, implementation of organized care, length of stay,
re-admission and institutionalization rates after discharge, dependency levels, and complication rates.
Results: Compared with the patients in the UC arm, the patients in the CP arm had a significantly lower risk of
mortality at 7 days (OR = 0.10; 95% CI 0.01 to 0.95) and significantly lower rates of adverse functional outcomes,
expressed as the odds of not returning to pre-stroke functioning in their daily life (OR = 0.42; 95 CI 0.18 to 0.98).
There was no significant effect on 30-day mortality. Compared with the UC arm, the hospital diagnostic and
therapeutic procedures were performed more appropriately in the CP arm, and the evidence-based key
interventions and organized care were more applied in the CP arm.
Conclusions: CPs can significantly improve the outcomes of patients with ischemic patients with stroke, indicating
better application of evidence-based key interventions and of diagnostic and therapeutic procedures. This study
tested a new hypothesis and provided evidence on how CPs can work.
Trial registration: ClinicalTrials.gov ID: [NCT00673491].
Background
Stroke represents one of the major public-health issues
worldwide [1-4]. The American Stroke Association has
reported that obstacles in translating scientific advances
into clinical practice are often related to fragmentation
caused by inadequate integration of facilities and
professionals that should closely collaborate [5]. This
potentially contributes to the high morbidity, mortality,
and economic cost of stroke [5-7]. Other studies have
suggested that establishing well-organized, multidisci-
plinary care can help improve the quality of the service
delivered and reduce the mortality rates associated with
stroke [8,9]. According to the Helsingborg Declaration of
2006 on European Stroke Strategies, all patients should
have access to a continuum of care, from stroke units
in the acute phase to appropriate rehabilitation and
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secondary prevention measures [10]. Consequently, to
improve the outcome, research and development priori-
ties were identified: the optimization of the use of multi-
disciplinary teams, the development of better ways to
deliver education to professionals and the public, the
implementation of evidence-based care, and the evalua-
tion of different models of stroke services [10].
The Australian National Stroke Foundation suggests
that all patients with stroke who are admitted to the hos-
pital should be managed using a clinical pathway (CP)
[11]. This recommendation was made using a body of
evidence from the Cochrane Collaboration but care
should be taken in its application [11-13]. Despite conti-
nuing interest in implementing CPs, the evidence base
for their effectiveness remains inconclusive [14]. There-
fore, the purpose of the Clinical Pathways for Effective
and Appropriate Care (CPEAC) Study (ClinicalTrials.gov
number: NCT00673491) was to determine whether CPs
can improve quality of care. The main objective was to
determine whether CPs are more effective than usual
care in treating patients with stroke, and whether CPs
reduce both patient mortality and improve patient out-
comes. The secondary objectives were to determine
whether CPs increase the appropriateness of the care
provided and to determine whether CPs help in imple-
menting organized care in stroke-care facilities.
Methods
Ethics approval and funding
The project received ethical clearance as a prerequisite of
approval for funding from the Italian Ministry of Health.
The CPEAC study was approved by the ethics committe
of Ancona, Marche Region, Italy, and the research was
carried out in compliance with the Declaration of Helsinki.
The managers in each unit consented to their clinic taking
part in the trial. Patient consent to be randomized to the
intervention or control arms was not obtained, because
the study design required randomization to occur at the
unit level. However, all individual patients gave consent to
participate in the study and had the opportunity to with-
draw from the study at any time. All patient data were
managed in accordance with the Italian Data Protection
Act [15]. The CPEAC Study was promoted and funded by
the Italian Ministry of Health (Special Programs art. 12 bis
D.lgs 229/99) and Marche Region [15].
Design overview
The CPEAC Study was designed as a multicenter cluster
randomized controlled trial (cRCT), in which patients
with stroke were randomized either to the experimental
(CP) group or to the non-intervention (usual care; UC)
group [15]. The study was designed in accordance with
the CONSORT statement for cRCTs [16]. It was carried
out during the period July 2005 to May 2007, and involved
a sample of Italian hospitals. A cluster design was used
because of the ethical and logistical issues associated with
the implementation of CPs, which involves a series of
complex actions at the institutional level [17-23]. A pilot
study to define baseline levels of performance has been
described previously [24].
Setting
Thirty-four units based in nine Italian regions were invited
to participate in the study (Figure 1); of these, twenty-nine
units expressed interest in implementing stroke CPs, and
were assessed for eligibility [15]. The selection of the units
and the final randomization was based on the comparabil-
ity of their location, patient population and volume, facil-
ities, and teaching status. To participate in the study, the
administrators of the units had to allow the institution to
be allocated to either of the two research groups (CP or
current practice) for a period of 1 year, and had to agree
not to implement a CP for the acute care and/or rehabili-
tation of stroke if their institution was assigned to the UC
group. Nine units were excluded because they did not
meet the inclusion criteria, and five units withdrew after
the project commenced, following a decision from their
management (three units withdrew after the project pre-
test and two units withdrew after the project began). One
unit could not provide reassurance that they would not
implement a CP if assigned to the control group, and
therefore were excluded from the study sample. The
remaining 14 units were stratified according to the avail-
ability of a stroke unit and to the teaching status of the
unit, and the strata were randomized to one of the two
arms. A simple randomization procedure was carried out
in each stratification sample before the intervention, and
patient randomization was carried out using a computer-
generated sequence with allocation concealment. Blinding
of patients and clinicians was not possible [15]. The CP
and UC groups each had seven hospitals assigned to them;
both groups contained hospitals with a stroke unit, and
both included one teaching hospital. The mean number of
beds was 405 in the CP group, and 409 in the UC group.
Calculation of study sample
A calculation was made to identify the sample size needed
to detect a significant difference in the 30-day mortality
rate [15]. Because of the mortality of patients with
ischemic stroke has been reported to range from 8% to
17%, we expected that a similar difference in our sample
would be required to evaluate CP as effective [3,25,26].
We consider this estimate reasonable because in the pilot
study that we performed previously to the main trial, we
observed an overall in-hospital mortality of 19.76%, which
is consistent with the higher levels of mortality reported in
the literature [24]. Therefore, as the expected mortality
rate of patients with ischemic stroke would be 8% to 17%,
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within 30 days of the incident we expected that the CP
intervention would succeed in limiting mortality to 8%,
and would therefore be clinically relevant. Based on this
goal, a sample size of 476 patients (238 in each group) was
required for the study to have 80% power at the 5% signifi-
cance level. The sample-size calculation was performed in
accordance with standard criteria for a cRCT
[16,19,22,27]. The sample size was adjusted using an infla-
tion factor of 1.43 to account for cluster randomization:
seven clusters per trial arm, with a cluster size of thirty-
four patients and an intra-cluster correlation coefficient
(ICC) of 0.018 [15,28-30].
Participants
The sample included all consecutive patients admitted to
the hospitals during the experimental period with a prin-
cipal diagnosis of acute ischemic stroke (International
Classification Diseases, Ninth Revision. Clinical Modifica-
tion (ICD-9CM) code 434.91). To be included, patients
had to be at least 18 years of age and admitted within 24
hours of stroke onset. Patients with hemorrhagic strokes
(all ICD-9CM codes included in code 431) or transient
ischemic attacks (ICD-9CM code 435.9) were excluded.
Baseline was verified by comparing the two groups on
admission both at the individual level (patient demo-
graphics and characteristics) and at the institutional/clus-
ter level (availability of healthcare facilities, technologies,
and human resources).
Randomization and interventions
The project started at each unit with a grand round that
outlined the project protocol. To facilitate project imple-
mentation, a healthcare worker experienced in CPs was
assigned to each unit in the experimental group. The
Figure 1 Overview of randomization.
Panella et al. BMC Medicine 2012, 10:71
http://www.biomedcentral.com/1741-7015/10/71
Page 3 of 12
teams included internal-medicine physicians, neurolo-
gists, physiatrists, epidemiologists, physiotherapists,
occupational therapists, nurses, speech therapists, hospi-
tal pharmacists, psychologists, social workers, and sup-
port staff. The teams were formed on a voluntary basis;
they received 3 days of training in quality improvement
and in the development of CPs. To ensure the interven-
tion was standardized, the teams also received a package
including evidence-based key interventions and indica-
tors provided by senior investigators of the Evidence-
Based Medicine (EBM) unit of the Regional Healthcare
Agency of Marche and the University of Eastern Pied-
mont [31-34]. The teams developed their CPs over a
6-month period (for examples of CPs, see Additional file
1, Additional file 2). All groups analyzed their care pro-
cesses, reviewed best evidence, defined the appropriate
goals of the pathways, and compiled the results into
protocols and documentation [14,35-37]. After develop-
ment, the CPs were analyzed by the EBM unit of the
Regional Healthcare Agency of Marche, and were judged
consistent with current recommendations for the diag-
nosis and treatment of stroke. After validation of the
CPs, each unit team educated its staff in the use of the
CP and monitored its use. This meant that the CPs
used in the study were not completely identical because
of organizational adaptations at some sites [11]; how-
ever, all adhered substantially to existing Italian guide-
lines on the hospital treatment and rehabilitation of
stroke, as described by Gensini et al. [33] and Provin-
ciali [38].
Outcomes and follow-up
The primary outcome measure was 30-day mortality after
stroke [15] defined as the proportion of ischemic stroke
events that were fatal within 30 days of onset. Stroke
fatality was chosen as the main outcome because it is
clinically relevant, objectively measured, and reliably
coded [8]. The effect of CP intervention was analyzed
with respect to 7-day mortality, length of in-hospital stay,
hospital re-admission rates, institutionalization rates after
hospital discharge, dependency levels, and complication
rates along the entire continuum of care [15]. The quality
of the care provided to the patients was assessed by mon-
itoring the implementation of evidence-based practice.
The implementation of organized care at the cluster level
was also evaluated. The list of indicators has been
described previously in detail [15].
Data collection
Local staff prospectively collected the data for both the
intervention and the control groups. The staff were not
given an incentives for data collection. Staff members
were trained in data collection at two educational
events. Data were collected using a standardized data-
extraction tool that used web technology, and were
anonymously entered into a secure database housed at
the University of Eastern Piedmont. Mortality data were
extracted from the Italian National Register of Mortality,
which is based on local registers that are completed and
used in each Health Authority at the Healthcare District
level. These registers are uploaded in real time when a
death occurs, and are matched monthly with the Muni-
cipality register for births and deaths. Completion of
these registers is compulsory by the doctor certifying
the death (deaths both at home or in medical institu-
tions) and there is a national procedure for monitoring
the quality and reliability of diagnosis data. In the cur-
rent study, we did not have any particular problems
about reliability of diagnosis of death because we fol-
lowed up two cohorts of people affected by ischemic
stroke, and when a death occurred, we verified the con-
cordance of the cause of death recorded in the register
with the pre-existing diagnosis of stroke.; the concor-
dance of the two was 100%.
Statistical analysis
The study design was based on that described previously
by Campbell et al., [17] and on the Consort Statement
for cRTCs, and the statistical analysis was performed
accordingly [27] by the research team. The Fisher exact
and Kruskal-Wallis tests for categorical and continuous
variables, respectively, were performed at the cluster
level. In addition, differences in the rates of 7-day and
30-day mortality and of return to pre-stroke functioning
in daily life between groups and according to each vari-
able under study were evaluated at the individual level
using random-effects logistic regression, accounting for
the clustering effect [15,39,40]. Variables were included if
significant at the 0.10 level (backward approach), with
the exception of gender, which was forced to entry. The
presence of multicollinearity, interaction, and higher
power terms was assessed to check final model validity.
Patient outcomes were described according to gender
(male); comorbidities (based on their Charlson-Deyo
index, patients were categorized as having 0 to 1 or > 1
comorbidities) [41]; medical complications (at least one
complication); admission to stroke unit (yes/no); access
to organized care (based on organized care index as hav-
ing 0 to1 or > 1 score) [8]; management by a stroke team
(yes/no); use of antithrombotic drugs (antiplatelet or
anticoagulant during the stay); and assessment of rehabi-
litation needs (yes/no). Because the assessment of rehabi-
litation needs does not have any effect on mortality, it
was not included in the model for explaining mortality,
but was included in the model for return to functional
pre-stroke status. Significance was defined as P < 0.05
(two-sided). All analyses were intention-to-treat and
were carried out using the software programs Statistica
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7.1 (StatSoft, USA) and Stata (version 10; StataCorp LP,
College Station, TX, USA).
Results
Baseline data
The final sample consisted of 476 patients (238 in each
group). As shown in Table 1, patients in the CP group
had higher rates of hypertension, peripheral vasculopa-
thy, and dementia rates, and a higher male prevalence,
whereas the UC group had higher rates of diabetes and
chronic obstructive pulmonary disease. No overall differ-
ences were found at the cluster level (Table 2).
Outcomes and estimation
Table 3 shows the discharge status of all patients
according to the type of treatment received and various
outcomes of care. The 7-day and 30-day mortality rates
were lower in the CP group, but the difference was not
significant, although there was a trend towards signifi-
cance for the 7-day death rates. There were better
results in the CP group for most of the secondary out-
comes (rates of return to pre-stroke functioning in daily
life, pressure-sore rates, and overall and in-hospital
complication rates), except for the average length of
stay, which was shorter in the UC group.
With regard to implementation of evidence-based key
interventions into daily practice through the continuum
of care, these were much more frequently used for the
CP than for the UC groups (Table 4). Similarly, orga-
nized care was more frequently used for the CP group
(Table 5). The proportion of patients receiving orga-
nized care was also significantly higher in the CP group
than in the UC group.
Ancillary analyses
The results of the multivariate random-effect logistic
models predicting the 7-day and 30-day mortality and
the rates of return to pre-stroke functioning in daily life
are shown in Table 6. After adjusting for gender, comor-
bidities, complications, use of stroke unit, organized care,
stroke team, and antithrombotic therapy, patients in the
CP group had a significantly lower risk of 7-day in-hospi-
tal death (OR = 0.10; 95% CI 0.01 to 0.95) and a signifi-
cantly higher probability of returning to pre-stroke
functioning in their daily life (0.42; 0.18 to 0.98) com-
pared with patients in the UC group.
Table 1 Demographic characteristicsa, b
Characteristics Clinical pathway, n = 238 No intervention, n = 238 Between-group difference, OR
(95% CI)
P-valueb
Age, years (mean ± SD) 74.5 ± 10.8 74.0 ± 11.7 - 0.61
Male gender 138/238 (58.0) (51.4 to 64.3) 98/238 (41.2) (34.9 to 47.7) 1.97 (1.35 to 2.89) < 0.001
Previous stroke 50/215 (23.3) (17.8 to 29.5) 57/207 (27.5) (21.6 to 34.2) 0.80 (0.50 to 1.27) 0.32
Current smoking status 29/229 (12.7) (12.4 to 22.5) 25/219 (11.4) (3.9 to 11.0) 1.13 (0.61 to 2.07) 0.77
Hypertension 132/229 (57.6) (51.0 to 64.1) 103/219 (47.0) (40.3 to 53.9) 1.53 (1.04 to 2.27) 0.03
Heart failure 86/229 (37.5) (30.0 to 42.8) 78/219 (35.6) (30.6 to 43.8) 1.09 (0.73 to 1.63) 0.69
Coronary heart disease 21/229 (9.2) (5.8 to 13.7) 29/219 (13.2) (9.1 to 18.5) 0.66 (0.35 to 1.25) 0.18
Peripheral vasculopathy 73/229 (31.9) (25.9 to 38.3) 46/219 (21.0) (15.8 to 27.0) 1.76 (1.12 to 2.76) < 0.01
Diabetes mellitus 52/229 (22.7) (17.4 to 28.7) 73/219 (31.5) (27.1 to 40.0) 0.59 (0.38 to 0.91) 0.01
Diabetes mellitus (organ pathology) 7/229 (3.1) (1.2 to 6.2) 9/219 (4.1) (1.9 to 7.8) 0.74 (0.24 to 2.20) 0.62
COPD 24/229 (10.5) (6.8 to 15.2) 51/219 (23.3) (17.9 to 29.5) 0.48 (0.28 to 0.83) < 0.01
Cerebrovascular pathology 60/229 (26.2) (20.6 to 32.4) 82/219 (37.4) (31.0 to 44.2) 0.59 (0.39 to 0.90) 0.01
Pressure ulcer 4/229 (1.8) (0.5 to 4.4) 11/219 (5.0) (2.5 to 8.8) 0.35 (0.09 to 1.22) 0.06
Hemiplegy 16/229 (7.0) (4.0 to 11.1) 22/219 (10.1) (6.4 to 14.8) 0.67 (0.33 to 1.38) 0.31
Nephropathy 10/229 (4.4) (2.1 to 7.9) 13/219 (5.9) (3.2 to 9.9) 0.72 (0.29 to 1.81) 0.52
Dementia 24/229 (10.5) (6.8 to 15.2) 10/219 (6.0) (2.2 to 8.2) 2.45 (1.08 to 5.63) 0.02
Hepatopathy 7/229 (3.1) (1.2 to 6.2) 6/219 (2.7) (1.0 to 5.9) 1.12 (0.33 to 1.82) 1
Cancer
Solid metastasis 2/229 (0.9) (0.1 to 3.1) 3/219 (1.4) (0.3 to 4.0) 0.63 (0.07 to 4.70) 0.68
Leukemia 2/229 (0.9) (0.1 to 3.1) 3/219 (1.4) (0.3 to 4.0) 0.63 (0.07 to 4.70) 0.68
Lymphoma 1/229 (0.4) (0.0 to 2.4) 0/219 (0.0) (0.0 to 1.7) 1.08 (0.14 to 1.92) 1
Others 11/229 (4.8) (2.4 to 8.4) 19/219 (8.7) (3.8 to 14.7) 0.53 (0.23 to 1.21) 0.10
aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).
bValues are n/total n (%) (95% CI) unless otherwise indicated.
cP-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.
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Discussion
Interpretation
The main finding of this study is that care delivered using
CPs to patients with stroke was significantly more evi-
dence-based than that delivered to patients with stroke
receiving UC, and this seemed to translate to more effec-
tive treatment, because implementation of CPs resulted in
a significant improvement of the outcomes.
There are several potential (and not mutually exclusive)
explanations for these results, ranging from selection bias
to improved performance. Selection bias may have
occurred both at the individual and cluster levels. At the
cluster level, no differences emerged; however, after ran-
domization, some differences were seen between the CP
and non-CP groups at the individual level. Therefore,
interpretation of the outcomes before randomization
could have been biased. Moreover, we could not use the
National Institute of Health Stroke Scale (NHISS),
because the study started before validation of this instru-
ment in 2009 [42]. Patient assessment before admission
was partly performed, therefore the severity of stroke was
not properly assessed. Except for mortality measures, we
found a significant drop in sample size for certain out-
comes in the non-intervention group. Thus, this may
limit our findings regarding outcome improvement.
However, CP use remained a significant determinant of
the improved patient outcomes even after adjusting for
potential confounders, including comorbidities at base-
line and complications during the hospital stay. There-
fore, the influence of selection bias, if any, is likely to be
minor [43].
A second possible explanation for our findings is the dif-
ferent use of organized care in the two groups. The use of
organized care and the access to the stroke units was were
significantly higher in the CP group. Because use of orga-
nized care and stroke units are integrated approaches to
managing stroke and are strong evidence-based indepen-
dent predictors of in-hospital mortality, they were used as
‘active components’ promoted by the implementation of
the CP [8,24]. Therefore, the observed improvements in
organized care and in use of stroke units and their positive
effect on patient outcome were expected as part of the
intervention.
Generalizability
With regard to outcomes, our results show how evi-
dence-based care can be effectively implemented in real-
world settings [6,11]. Indeed, the use of evidence-based
care was significantly improved in the CP group, which
also made better use of the organized care, as mentioned
Table 2 Hospital characteristicsa
Hospital characteristics Clinical pathway, n = 7b No intervention, n = 7b P-valuec
Setting (University hospital (%) 1 (14.3) 1 (14.3) 1
Healthcare workers dedicated to stroke care, n (mean ± SD)
Physician 46 (6.6) (0.97) 49 (7.0) (1.29) 0.49
Nurse 80 (11.4) (1.51) 88 (12.6) (1.72) 0.21
Physiotherapist 28 (4.0) (1.29) 24 (3.4) (1.39) 0.44
Auxiliary nurse 11 (1.6) (0.79) 10 (1.4) (0.53) 0.69
Speech therapist 2 (0.3) (0.49) 1 (0.1) (0.38) 0.55
Availability of medical equipment in emergency department, n (%)
24-hour ED 7 (100) 7 (100) 1
CT brain scan 7 (100) 7 (100) 1
MRI brain scan 5 (71.4) 7 (100) 0.17
Eco-color Doppler 5 (71.4) 7 (100) 0.17
Echocardiography 5 (71.4) 7 (100) 0.17
Transcranic Doppler 4 (57.1) 2 (28.6) 0.35
Availability of continuous monitoring during stay, n (%)
Electrocardiography 5 (71.4) 6 (85.7) 0.35
Finger-press 5 (71.4) 6 (85.7) 0.35
Saturimeter 5 (71.4) 6 (85.7) 0.35
Pulse oximeter 4 (57.1) 4 (57.1) 1
24-hour investigations
Hematochemical 5 (71.4) 6 (85.7) 0.35
Neurological 5 (71.4) 4 (57.1) 0.60
COPD, chronic obstructive pulmonary disease; CT, computed tomography; ED, emergency department.
aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).
bValues are n/total n (%) (95% CI) unless otherwise indicated.
cP-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.
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Table 3 The outcome indicatorsa, b
Variables Clinical pathway,
n = 238
No intervention,
n = 238
Between-group difference, OR
(95% CI)
P-valuec
In-hospital death rate within 30 days of admission to hospital 18/238 (7.6) (4.5 to
11.7)
25/238 (10.5) (6.9 to
15.1)
0.70 (0.35 to 1.37) 0.34
In-hospital death rate within 7 days of admission to hospital 7/238 (2.9) (1.2 to 6.0) 16/238 (6.7) (3.6 to 10.2) 0.42 (0.15 to 1.11) 0.05
In-hospital death rate within 30 days of stroke attack 18/238 (7.6) (4.5 to
11.7)
25/238 (10.5) (6.9 to
15.1)
0.70 (0.35 to 1.37) 0.34
Post-discharge death rates (1, 3, 6, 12 months after discharge) 3/53 (5.7) (1.2 to 15.7) 0/27 (0.0) (0.0 to 12.8) 1.54 (1.31 to 1.81) 0.55
In-patients length of stay, n (mean ± SD) 229 (11.78 ± 6.6) 219 (10.88 ± 7.9) - 0.19
Within 9 days of length of stay in hospital patients’ rate 94/227 (41.4) (34.9 to
48.1)
114/215 (53.0) (46.1 to
59.8)
1.60 (1.08 to 2.37) 0.02
Pressure-sore incidence rate 4/229 (1.7) (0.5 to 4.4) 12/219 (5.5) (2.9 to 9.4) 0.31 (0.08 to 0.94) 0.04
Overall in-hospital complications rate 53/229 (23.1) (17.8 to
29.2)
67/219 (30.6) (24.6 to
37.2)
0.68 (0.44 to 1.06) 0.09
Overall post-discharge complications rate 12/103 (11.7) (6.2 to
19.5)
0/27 (0.0) (0.0 to 12.8) 1.30 (0.98 to 1.43) 0.07
Institutionalization at discharge 26/92 (28.3) (19.4 to
38.6)
15/64 (23.4) (14.0 to
36.2)
1.29 (0.58 to 2.87) 0.58
In-hospital re-admission rate (within 30 days of discharge) 0/211 (0.0) (NC) 0/194 (0.0) (NC) NC NC
Return to pre-stroke functioning in daily life rate (with ADL/case mix adjustment) 97/208 (46.6) (39.1 to
52.9)
22/90 (24.4) (16.0 to
34.6)
2.70 (1.50 to 4.88) < 0.001
Return to pre-stroke functioning in daily life rate at follow-up at 3 months (with ADL/case mix
adjustment)
62/101 (61.4) (51.2 to
70.9)
5/9 (55.5) (21.2 to 86.3) 1.27 (0.27 to 5.92) 0.73
ADL, Activities of daily living; NC, Not calculable
aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).
bValues are n/total n (%) (95% CI) unless otherwise indicated.
cP-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.
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Table 4 The process indicatorsa, b
Variables Clinical pathway,
n = 238
No intervention, n =
238
Between-group difference, OR
(95% CI)
P-valuec
Information, advice, and support from the multidisciplinary team given to the patients (and with their
consent, to the caregivers)
204/204 (100) (98.2 to
0.0)
115/133 (86.5) (81.2
to 92.3)
1.16 (1.08 to 1.24) < 0.001
Use of clinical protocols (see protocol) 221/229 (96.5) (93.2
to 98.5)
83/139 (59.7) (51.1 to
67.9)
18.64 (8.14 to 44.31) < 0.001
Use of CT/MRI brain scan within 48 hours of admission 223/229 (97.4) (94.4
to 99.0)
209/219 (95.4) (91.8
to 97.8)
1.78 (0.58 to 5.61) 0.31
Aspirin treatment within 48 hours of admission 157/188 (83.5) (77.4
to 88.5)
146/196 (74.5) (67.8
to 80.4)
1.73 (1.02 to 2.75) 0.03
Swallow screen test on day of admission 211/213 (99.1) (96.6
to 99.9)
83/95 (87.4) (79.0 to
93.3)
15.25 (3.14 to 100.96) < 0.001
Blood pressure assessment 173/197 (87.8) (82.3
to 92.0)
78/191 (40.8) (33.8 to
48.2)
10.44 (6.06 to 18.10) < 0.001
ECG/ECD within 24 hours of admission 168/181 (92.8) (90.4
to 96.9)
205/218 (94.0) (90.0
to 96.8)
0.82 (0.35 to 1.94) 0.69
Continuous monitoring within 48 hours of admission (see protocol) 85/229 (37.1) (30.8 to
43.7)
21/219 (9.6) (6.0 to
14.3)
5.57 (3.21 to 9.73) < 0.001
Before discharge total assessment (see protocol) 200/215 (93.0) (89.4
to 96.3)
176/200 (88.0) (85.1
to 93.9)
1.82 (0.88 to 3.77) 0.09
Use of discharge plan (and communication) 73/214 (34.1) (25.9 to
38.3)
41/200 (20.5) (13.8 to
24.5)
2.01 (1.26 to 3.21) < 0.01
Use of SIGN guideline-based discharge plan 188/207 (90.8) (86.0
to 94.4)
0 (0.0) (0.0 to 3.7) 999.4 (137.0 to 20374.0) < 0.001
Use of discharge summary and information (information pack) 190/214 (88.8) (77.5
to 87.6)
134/200 (67.0) (54.4
to 67.7)
3.90 (2.26 to 6.67) < 0.001
Before discharge assessment with FIM scale 201/209 (96.2) (93.4
to 98.5)
76/168 (45.2) (39.0 to
54.6)
30.41 (13.49 to 71.24) < 0.001
Follow-up assessment at 3 months with FIM scale 82/86 (95.3) (89.9 to
98.9)
9/29 (31.0) (16.1 to
50.0)
45.56 (11.20 to 205.58) < 0.001
ABC, Airway, Breathing, Circulation; CT, computed tomography; ECD, Eco-color doppler; FIM, Functional independence measure; MRI, magnietic resonance imaging; SIGN, Scottish Intercollegiate Guideline Network.
aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).
bValues are n/total n (%) (95% CI) unless otherwise indicated.
cP-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.
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Table 5 The organized care indicatorsa, b
Variables Clinical pathway,
n = 238
No intervention,
n = 238
Between-group difference, OR
(95% CI)
P-valuec
Admission to stroke unit 132/226 (58.4) (51.7 to
64.9)
32/197 (16.2) (11.4 to
22.2)
7.24 (4.45 to 11.82) < 0.001
Stay in stroke unit within 24 hours after admission and until the end of in-hospital
rehabilitation
94/117 (80.3) (72.0 to
87.1)
4/31 (12.9) (3.6 to 29.8) 27.59 (8.06 to 104.10) < 0.001
Use of case managers (physiotherapists, occupational therapists, nurses specialized in
stroke care)
223/224 (99.6) (97.5 to
100.0)
104/192 (54.2) (46.8 to
61.4)
188.69 (27.93 to 3697.86) < 0.001
Use of stroke team 220/222 (99.1) (96.8 to
99.9)
82/126 (65.1) (56.1 to
73.4)
59.02 (13.57 to 360.39) < 0.001
Assessment of rehabilitation needs by a member of the stroke team within 48 hours after
admission
217/225 (96.4) (93.1 to
98.5)
126/219 (57.5) (50.7 to
64.2)
20.02 (9.04 to 46.12) < 0.001
Patients’ needs assessment and planning rate for post-discharge services 201/209 (96.2) (92.6 to
98.3)
68/168 (40.5) (33.0 to
48.3)
32.84 (15.08 to 73.81) < 0.001
Follow-up rate within 3 months after discharge (by specialist/stroke team) 63/64 (98.4) (91.6 to
100.0)
0/27 (0.0) (0.0 to 12.8) 28.00 (4.09 to 191.88) < 0.001
aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).
bValues are n/total n (%) (95% CI) unless otherwise indicated.
cP-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.
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above. These findings were apparent despite the com-
plexity of objective evaluation of stroke, as has been
reported by the primary stroke center certification pro-
gram and the performance measurements of the Joint
Commission [44-46]. Our findings were mostly based on
short-term outcomes. Long-term and/or more qualitative
outcomes, such as patient satisfaction and quality of life,
were not evaluated. This was mainly due to the informa-
tion system, especially in the method of documenting
and collecting data (clinical records, paper-based abstrac-
tion tools), and could also be a limitation of our findings
[12,47].
In the study, we found a significant reduction only in 7-
day mortality, whereas 30-day mortality was not signifi-
cantly affected by the use of CPs. The 7-day mortality
depends more on the early treatment of patients, but no
specific protocol for factors influencing early arrival was
implemented in the CP. Therefore, it is possible that the
CP hospitals might have admitted patients earlier, and
this would have artificially reduced their short-term in-
hospital mortality rate. Although we did not have specific
data on the events before admission, it is reasonable to
assume that the randomization process would have con-
trolled for this possible bias. However, after risk adjust-
ment, the CP method remained a significant determinant
of reduced 7-day mortality. Moreover, at discharge,
patients in the CP group had a significantly higher rate of
return to pre-stroke functioning compared with the UC
group, and the process of care was significantly more
consistent with evidence-based care. Based on our find-
ings and those of other authors, we consider it reasonable
to believe that the better outcomes observed for the CP
group are attributable to an improvement in the quality
of care achieved with the use of CPs [11,44,48,49].
A limitation of our findings is that we could not
examine the effect of CPs on the use of reperfusion
therapy (tissue plasminogen activator; tPA), because in
Italy the non-experimental use of this procedure was
authorized only after the conclusion of this study. Early
treatment based on tPA involves the expertise of several
professionals, which can result in poor coordination or
inefficiencies in the care process. Indeed, several studies
have shown that tPA use in acute ischemic strokes can
be enhanced by organized care, routine use of protocols,
and multidisciplinary teamwork, which the current
study also showed identified as active components of
the implemented CP [48,50]. Therefore, our findings
suggest that the use of CPs through the implementation
of better care might also be helpful for the effective use
of tPA, but specific studies are required.
Because CPs are quality improvement initiatives it was
not possible to blind the intervention or the assessment
Table 6 Multivariate analysis: 7-day and 30-day mortality and pre-stroke status (not return)
Variables
Outcome Pathway Male
gender
Comorbidities Complications Stroke
unit
Organized
care
Stroke
team
Antithrombotic
treatment
Assessment of
rehabilitation needs
7-day mortality
P
value
0.04 0.89 0.85 0.06 0.13 0.65 0.18 0.07 -
Odds ratio 0.10 1.14 1.27 4.71 0.24 0.54 0.17 0.21 -
-95%
CI
0.01 0.19 0.11 0.95 0.04 0.04 0.01 0.04 -
+95%
CI
0.95 6.75 14.82 23.37 1.52 8.01 2.36 1.16 -
30-day mortality
P
value
0.12 0.78 0.15 0.00 0.08 0.81 0.12 0.03 -
Odds ratio 0.30 0.84 2.79 7.17 0.29 0.74 0.15 0.25 -
-95%
CI
0.06 0.24 0.70 2.22 0.07 0.06 0.01 0.07 -
+95%
CI
1.39 2.92 11.19 23.15 1.16 8.54 1.68 0.85 -
Pre-stroke status (not return)
P
value
0.04 0.76 0.81 0.00 0.84 0.11 0.08 0.22 0.53
Odds ratio 0.42 1.10 1.09 5.72 0.93 0.09 0.12 0.62 0.33
-95%
CI
0.18 0.60 0.54 2.36 0.49 0.00 0.01 0.29 0.01
+95%
CI
0.98 2.00 2.18 13.87 1.80 1.73 1.27 1.34 10.85
bValues are n/total n (%) (95% CI) unless otherwise indicated.
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of the outcomes. Therefore it could have been that the
awareness and attention associated with receiving a new
intervention (Hawthorne effect) was responsible, in part,
for the improved outcomes associated with the CPs.
Given the type of intervention, a cluster randomized
design was the most appropriate design to use
[19,22,27,40]. However, these studies have some limita-
tions when applied to CPs [51]. Indeed, context level
adaptation, which is essential for the pathways to suc-
ceed, may be perceived as inappropriate in the trial
design. Also, it may be difficult to replicate and main-
tain the original intervention. To reduce such issues, we
implemented pathways that combined local standards
with evidence-based indicators to maintain the integrity
of the intervention at each site [21,52].
Conclusions
This study adds evidence in favor of the notion that,
compared with UC, CPs can help to provide better,
comprehensive, and more specialized care to patients
affected by stroke. However, additional studies are
needed to further understand the cost-effectiveness of
CPs and how to pass the critical point at which adher-
ence to a pathway decreases [53-55].
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